Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Circulating tumor DNA (ctDNA) provides more actionable risk stratification than pathologic stage in resected upper tract disease. Patients who test ctDNA negative exhibit a low 20% to 30% risk of recurrence, making active surveillance reasonable to avoid toxic, marginally effective adjuvant therapies. Conversely, ctDNA positivity behaves like occult metastatic disease with recurrence rates approaching 95%, prompting clinicians to bypass adjuvant platinum for full-dose enfortumab vedotin plus pembrolizumab.

Related Insights

ctDNA is not a simple positive/negative binary test. Like PSA in prostate cancer, the quantitative level of ctDNA correlates with patient outcomes. Higher levels indicate a worse prognosis and a faster time to relapse, allowing for more nuanced risk stratification beyond a simple presence or absence of the biomarker.

Circulating tumor DNA (ctDNA) is a powerful tool in bladder cancer. A positive result post-surgery is a strong indicator for initiating adjuvant therapy. However, a negative result does not guarantee a cure, as a notable percentage of these patients still relapse, making clinicians cautious about withholding treatment based on a single negative test.

Circulating tumor DNA (ctDNA) testing is described as unequivocally the most prognostic tool available for colorectal cancer. Patients who remain serially negative have a minimal recurrence risk, while a positive result almost universally predicts a future clinical recurrence by 6-8 months.

Experts find a positive circulating tumor DNA (ctDNA) test more useful for informing a decision to start adjuvant therapy. A negative result is considered less helpful and doesn't provide the same level of reassurance or definitively rule out treatment, as the pivotal clinical trial was designed to address the ctDNA-positive scenario.

In early-stage non-small cell lung cancer, the presence of circulating tumor DNA before surgery is not a statistically significant predictor of survival. However, detecting ctDNA after curative-intent surgery is a strong negative prognostic indicator, highlighting the critical value of post-operative testing.

In adjuvant bladder cancer trials, ctDNA status is both prognostic and predictive. Patients with positive ctDNA after surgery are at high risk of relapse but benefit from immune checkpoint inhibitors. Conversely, ctDNA-negative patients have a lower risk and derive no benefit, making ctDNA a critical tool to avoid unnecessary, toxic therapy.

In muscle-invasive bladder cancer, patients whose cell-free DNA remains positive after surgery almost uniformly experience disease relapse. This makes ctDNA a powerful prognostic tool, akin to PSA in prostate cancer, for identifying patients at the highest risk.

Experts warn against over-interpreting a single negative ctDNA test after surgery, clarifying that these patients still face a significant 25-30% risk of recurrence. The biomarker's true prognostic power comes from serial testing that shows a patient remains persistently negative over time.

While a positive ctDNA test clearly signals the need for adjuvant therapy, a negative result is less actionable for deciding initial treatment. The key prognostic value comes from being *serially* undetectable over time, information that is not available when the immediate post-surgery treatment decision must be made.

Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) offer complementary information. Used together, they provide superior risk stratification. Patients negative on both tests have a >70% chance of a complete pathological response, while those positive on both have only a ~5% chance, demonstrating clear additive value.